FibroGen Initiates Phase 2 Trial Testing Pamrevlumab as a COVID-19 Treatment

FibroGen has initiated a phase 2 trial of its monoclonal antibody pamrevlumab for the treatment of hospitalized patients with acute COVID-19 infections.

Pamrevlumab is also being developed for treatment of idiopathic pulmonary fibrosis, locally advanced unresctable pancreatic cancer and Duchenne muscular dystrophy.

The multicenter trial just launched will assess the drug’s effect on blood oxygenation in 130 COVID-19 patients in the U.S.